News
Long-term follow-up of two trials of the addition of trastuzumab to chemotherapy for patients with early HER2-positive breast cancer continue to show improvements in overall and disease-free survival in patients after a median of 8·4 years’ follow-up. The two trials included 4046 patients who were HER2-positive. After completion of doxorubicin and cyclophosphamide chemotherapy, some patients were randomly assigned to receive trastuzumab plus paclitaxel then trastuzumab alone to complete a year of therapy, whereas others were randomly assigned a regimen that did not contain trastuzumab. A joint analysis of these trials, led by Edith Perez and colleagues, suggests that patients given trastuzumab after chemo therapy had better overall survival than those given trastuzumab (hazard ratio [HR] 0·63 [95% CI
0·54–0·73]; p
Long-term follow-up of two trials of the addition of trastuzumab to chemotherapy for patients with early HER2-positive breast cancer continue to show improvements in overall and disease-free survival in patients after a median of 8·4 years’ follow-up. The two trials included 4046 patients who were HER2-positive. After completion of doxorubicin and cyclophosphamide chemotherapy, some patients were randomly assigned to receive trastuzumab plus paclitaxel then trastuzumab alone to complete a year of therapy, whereas others were randomly assigned a regimen that did not contain trastuzumab. A joint analysis of these trials, led by Edith Perez and colleagues, suggests that patients given trastuzumab after chemo therapy had better overall survival than those given trastuzumab (hazard ratio [HR] 0·63 [95% CI
0·54–0·73]; p
